Max Planck Institute for Terrestrial Microbiology, Marburg, Germany.
Center for Synthetic Microbiology (SYNMIKRO), Marburg, Germany.
Appl Environ Microbiol. 2020 Oct 15;86(21). doi: 10.1128/AEM.01113-20.
In most ecosystems, bacteria exist primarily as structured surface-associated biofilms that can be highly tolerant to antibiotics and thus represent an important health issue. Here, we explored drug repurposing as a strategy to identify new antibiofilm compounds, screening over 1,000 compounds from the Prestwick Chemical Library of approved drugs for specific activities that prevent biofilm formation by Most growth-inhibiting compounds, which include known antibacterial but also antiviral and other drugs, also reduced biofilm formation. However, we also identified several drugs that were biofilm inhibitory at doses where only a weak effect or no effect on planktonic growth could be observed. The activities of the most specific antibiofilm compounds were further characterized using gene expression analysis, proteomics, and microscopy. We observed that most of these drugs acted by repressing genes responsible for the production of curli, a major component of the biofilm matrix. This repression apparently occurred through the induction of several different stress responses, including DNA and cell wall damage, and homeostasis of divalent cations, demonstrating that biofilm formation can be inhibited through a variety of molecular mechanisms. One tested drug, tyloxapol, did not affect curli expression or cell growth but instead inhibited biofilm formation by suppressing bacterial attachment to the surface. The prevention of bacterial biofilm formation is one of the major current challenges in microbiology. Here, by systematically screening a large number of approved drugs for their ability to suppress biofilm formation by , we identified a number of prospective antibiofilm compounds. We further demonstrated different mechanisms of action for individual compounds, from induction of replicative stress to disbalance of cation homeostasis to inhibition of bacterial attachment to the surface. Our work demonstrates the potential of drug repurposing for the prevention of bacterial biofilm formation and suggests that also for other bacteria, the activity spectrum of antibiofilm compounds is likely to be broad.
在大多数生态系统中,细菌主要以结构化的表面相关生物膜形式存在,这些生物膜对抗生素具有高度耐受性,因此是一个重要的健康问题。在这里,我们探索了药物再利用作为一种策略,以确定新的抗生物膜化合物,从 Prestwick 化学库中筛选了超过 1000 种已批准药物的化合物,以寻找具有特定活性的化合物,这些活性可以阻止生物膜的形成。大多数生长抑制化合物,包括已知的抗菌剂,也包括抗病毒剂和其他药物,也能减少生物膜的形成。然而,我们还确定了几种在仅观察到对浮游生物生长有微弱影响或无影响的剂量下具有抗生物膜活性的药物。使用基因表达分析、蛋白质组学和显微镜进一步研究了最特异的抗生物膜化合物的活性。我们观察到,这些药物中的大多数通过抑制产生生物膜基质主要成分卷曲菌的基因的表达来发挥作用。这种抑制显然是通过诱导几种不同的应激反应来实现的,包括 DNA 和细胞壁损伤以及二价阳离子的内稳态,这表明可以通过多种分子机制来抑制生物膜的形成。一种经过测试的药物 tyloxapol 既不影响卷曲菌的表达也不影响细胞生长,但通过抑制细菌附着到表面来抑制生物膜的形成。预防细菌生物膜的形成是当前微生物学的主要挑战之一。在这里,我们通过系统地筛选大量的已批准药物,以评估它们抑制 的生物膜形成的能力,从而确定了一些有前景的抗生物膜化合物。我们进一步证明了单个化合物的不同作用机制,从诱导复制应激到平衡阳离子内稳态再到抑制细菌附着到表面。我们的工作证明了药物再利用预防细菌生物膜形成的潜力,并表明对于其他细菌,抗生物膜化合物的活性谱可能很广泛。